1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > 2015 Big Pharma Outlook

2015 Big Pharma Outlook

  • July 2015
  • -
  • Datamonitor Healthcare

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on highperforming markets This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the industry will navigate headwinds in order to steer towards robust growth

What’s included in this report:

Analyst Outlook

Revenue Analysis

Therapy Area Analysis

Lifecycle Analysis

Strategy Analysis

Key questions answered:

What are the significant challenges and drivers facing Big Pharma out to 2024?

Which companies will propel revenue growth over the forecasts period?

Which companies will have leading market share gains and market share losses?

How are late stage pipelines positioned, and what are the most-coveted launch products?

Which therapy areas will experience the largest growth and decline?

What are the portfolio weightings of Big Pharma based on the lifecycle of products?

How is Big Pharma adopting lifecycle management strategies to increase value?

Table Of Contents

2015 Big Pharma Outlook
TABLE OF CONTENTS
5 ABOUT THIS REPORT
5 Analysis structure
5 Key questions answered
5 Highlights
7 ANALYST OUTLOOK
8 REVENUE ANALYSIS
8 Global revenue overview
9 Company revenue overview
13 Top 30 products in 2024
16 Big Pharma pipeline overview
17 Top 30 pipeline products
21 Company launch portfolios
24 Five-year launch analysis
29 Expiry revenue overview
30 Bibliography
31 THERAPY AREA ANALYSIS
31 Worldwide overview
31 Therapy area ranking
35 Oncology
39 Endocrine, metabolic, and genetic disorders
44 Central nervous system
48 Bibliography
50 LIFECYCLE ANALYSIS
51 Lifecycle management case studies
57 Biosimilars
60 Bibliography
63 STRATEGY ANALYSIS
63 How has Big Pharma adapted strategically to internal and external headwinds?
65 Targeted deal-making
66 Cost-cutting programs
68 Big Pharma emerging market presence
69 Bibliography
72 APPENDIX
72 Webinars
72 Forecast methodology

LIST OF FIGURES

8 Figure 1: Big Pharma's prescription pharmaceutical performance, by sales ($m) and growth
rate (%), 2011-24
9 Figure 2: Big Pharma ranking, 2007-24
10 Figure 3: Big Pharma waterfall ($m), 2014-24
16 Figure 4: Big Pharma's pipeline overview ranking in 2015
29 Figure 5: Big Pharma's risk-of-expiry sales, by expiry year ($m), 2014-22
31 Figure 6: Big Pharma therapy area sales ($bn), 2008-24
31 Figure 7: Therapy area ranking, 2007-24
35 Figure 8: Big Pharma oncology sales ($bn) and product growth drivers and resistors
35 Figure 9: Oncology waterfall overview, 2014-24
36 Figure 10: Oncology sales growth contribution market share, 2014-24
38 Figure 11: PD-1 and PD-L1 sales forecasts ($m), 2014-24
39 Figure 12: Big Pharma EMandGD sales ($bn) and product growth drivers and resistors, 2011-24
40 Figure 13: EMandGD waterfall overview ($m), 2014-24
40 Figure 14: EMandGD sales growth contribution market share, 2014-24
45 Figure 15: Big Pharma CNS sales ($bn) and product growth drivers and resistors
45 Figure 16: CNS waterfall overview, 2014-24
46 Figure 17: CNS sales growth contribution market share, 2014-24
50 Figure 18: Big Pharma lifecycle management, 2014-24
51 Figure 19: Big Pharma lifecycle portfolio weightings ($m), 2014-24
68 Figure 20: Big Pharma RandD spend ($bn), 2008-24
72 Figure 21: Datamonitor Healthcare's methodology

LIST OF TABLES

8 Table 1: Big Pharma peer set market share analysis
11 Table 2: Big Pharma sales, by company ($bn), 2014-24
13 Table 3: Big Pharma's top 30 products ($m), 2014-24
18 Table 4: Top 30 Big Pharma pipeline sales, by brand ($m), 2014-24
22 Table 5: Big Pharma launch portfolio sales, by company ($m), 2014-24
25 Table 6: Big Pharma product launch, by brand ($m), 2010-19
29 Table 7: Big Pharma's risk-of-expiry sales, by expiry year ($m), 2014-24
33 Table 8: Big Pharma sales by therapy area ($bn), 2014-24
57 Table 9: Big Pharma biosimilar sales ($m), 2015-24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025 Summary Endometriosis is an estrogen-dependent, chronic, inflammatory disease characterized by the appearance and growth of ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.